Cholinesterase inhibitors and methyl D-aspartate receptor antagonists delay cognitive decline by approximately six months in dementia patients; however, their safety in end-stage renal disease (ESRD) remains unclear. Here, BCHE is linked to stage 5 chronic kidney disease.